Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows - STAT

Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows - STAT
Business

Listen to this article

0%

LONDON An experimental Alzheimers drug from Biogen, designed with a novel approach, slowed patients cognitive decline in a mid-stage trial at roughly comparable rates as approved medicines, new data … [+1093 chars]

Leave A Comment

Comments are moderated and may take time to appear.

Comments

No comments yet. Be the first to comment!

Stay Connected